Cytochrome P450 pat 2: Genetics on inter-individual variability

Journal of Pharmacy Practice and Research

Volumn 38, Issue 3, 2008, Pages 226-229

  Ward, Michael B ^a   Sorich, Michael J ^a   McKinnon, Ross A ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAFFEINE; CITALOPRAM; CLOZAPINE; CODEINE; COUMARIN; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2C9; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DEXTROMETHORPHAN; DIAZEPAM; DRUG METABOLITE; NEUROLEPTIC AGENT; NICOTINE; OLANZAPINE; OMEPRAZOLE; OPIATE; PERHEXILINE; PHENYTOIN; PROTON PUMP INHIBITOR; SERTRALINE; THEOPHYLLINE; UNINDEXED DRUG; WARFARIN;

ALLELE; BLEEDING; BLOOD ANALYSIS; CATALYSIS; CHROMOSOME ABERRATION; CIGARETTE SMOKING; DNA DETERMINATION; DNA MICROARRAY; DRUG DOSE REDUCTION; DRUG METABOLISM; DRUG RESPONSE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; ENZYME SUBSTRATE; GENE DUPLICATION; GENE FUNCTION; GENE IDENTIFICATION; GENE NUMBER; GENE PROBE; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; LOW DRUG DOSE; MICROARRAY ANALYSIS; PHARMACOGENETICS; PHENOTYPE; POPULATION GENETICS; PROTEIN FAMILY; RECOMBINANT DNA TECHNOLOGY; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; URINALYSIS; WILD TYPE;

EID: 55449089745     PISSN: 1445937X     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.2055-2335.2008.tb00845.x     Document Type: Review

References (34)

1. Motulsky A. Drug reactions, enzymes and biochemical genetics. JAMA 1957; 165: 835-7.
2. Kalow W. Pharmacogenetics-heredity and the response to drugs. Philadelphia: WB Saunders Company; 1962.
3. Human Cytochrome P450 (CYP) Allele Nomenclature Committee. Allele nomenclature for cytochrome P450 enzymes. Available from .
4. Watanabe W. Polymorphic CYP genes and disease predisposition - what have the studies shown so far? Tox Lett 1998; 102-3: 167-71.
5. McKinnon RA, Sorich MJ, Ward MB. Cytochrome P450 Part I: multiplicity and function. J Pharm Pract Res; 38: 55-7.
6. McKinnon RA, Hall P de la M, Quattrochi LC, Tukey RH, McManus ME. Localization of CYP1A1 and CYP1A2 messenger RNA in normal human liver and in hepatocellular carcinoma by in situ hybridization. Hepatology 1991; 14: 848-56.
7. Schweikl H, Taylor JA, Kitareewan S, Linko P, Nagorney D, Goldstein JA. Expression of GYP1A1 and GYP1A2 genes in human liver. Pharmacogenetics 1993; 3: 239-49.
8. Tang BK, Zhou Y, Kadar D, Kalow W. Caffeine as a probe for CYP1A2 activity: potential influence of renal factors on urinary phenotypic trait measurements. Pharmacogenetics 1994; 4: 117-24.
9. Butler MA, Lang NP, Young JF, Caporaso NE, Vineis P, Hayes RB, et al. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992; 2: 116-27.
10. Pavanello S, Pulliero A, Lupi S, Gregorio P, Clonfero E. Influence of the genetic polymorphism in the 5-noncoding region of the CYP1A2 gene on CYP1A2 phenotype and urinary mutagenicity in smokers. Mutat Res 2005; 587: 59-66.
11. Sachse C, Brockmoller J, Bauer S, Roots I. Functional significance of a C>A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999; 47: 445-9.
12. Pianezza ML, Sellers EM, Tyndale RF. Nicotine metabolism defect reduces smoking. Nature 1998; 393: 750.
13. Takahashi H, Kashima T, Nomoto S, Iwade K, Tainaka H, Shimizu T, et al. Comparisons between in-vitro and in-vivo metabolism of(S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. Pharmacogenetics 1998; 8: 365-73.
14. Kirchheiner J, Brockmoller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 2005; 77: 1-16.
15. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachan SL, Farin FM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287: 1690-8.
16. Veenstra DL, Blough DK, Higashi MK, Farin FM, Srinouanprachan SL, Rieder MJ, et al. CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes. Clin Pharmacol Ther 2005; 77: 353-64.
17. Schwarz UI, Ritchie MD, Bradford Y, Li Chun, Dudek SM, Frye-Anderson A, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008; 358: 999-1008.
18. Wilkinson GR, Guengerich FP, Branch RA. Genetic polymorphism of S-mephenytoin hydroxylation. Pharm Ther 1989; 43: 53-76.
19. Desta Z, Zhao X, Shin JG, Flockhart DA Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002; 41: 913-58.
20. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006; 79: 103-13.
21. Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am J Gastroenterol 2006; 101: 1467-75.
22. Kurzawski M, Gawronska-Szklarz B, Wrzesniewska J, Siuda A, Starzynska T, Drozdzik M. Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients. Eur J Clin Pharmacol 2006; 62: 877-80.
23. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmcology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004; 369: 23-37.
24. Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60: 284-95.
25. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002; 3: 229-43.
26. Johansson I, Lundqvist F, Bertilsson L, Dahl ML, Sjoqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993; 90: 11825-9.
27. Daly AK, Brockmoller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996; 6: 193-201.
28. Caraco Y, Sheller J, Wood AJ. Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects. J Pharmacol Exp Ther 1999; 290: 413-22.
29. Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2006; 368: 704.
30. Sallustio BC, Morris RG. Assessment of interlaboratory performance in the provision of perhexiline therapeutic drug monitoring services in Australia. Ther Drug Monit 1999; 21: 389-94.
31. Hu Y, Oscarson M, Johansson I, Yue QY, Dahl ML, Tabone M, et al. Genetic polymorphism of human CYP2E1: characterization of two variant alleles. Mol Pharmacol 1997; 51: 370-6.
32. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals. J Pharmacol Exp Ther 1994; 270: 414-23.
33. McKinnon RA, Burgess WM, Hall P de la M, Gonzalez FJ, Roberts-Thomson SJ, McManus ME. Characterisation of CYP3A gene subfamily expression in human gastrointestinal tissues. Gut 1995; 36: 259-67.
34. McKinnon RA, Ward MB, Sorich MJ. A critical analysis of barriers to the implementation of pharmacogenomics into clinical practice. Ther Clin Risk Manag 2007; 3: 751-9.